Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.
Ontology highlight
ABSTRACT: Genetic defects in complement regulatory proteins can lead to severe renal diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathies, and age-related macular degeneration. The majority of the mutations found in patients with these diseases affect the glycoprotein complement factor H, the main regulator of the alternative pathway of complement activation. Therapeutic options are limited, and novel treatments, specifically those targeting alternative pathway activation, are highly desirable. Substitution with biologically active factor H could potentially treat a variety of diseases that involve increased alternative pathway activation, but no therapeutic factor H is commercially available. We recently reported the expression of full-length recombinant factor H in moss (
SUBMITTER: Michelfelder S
PROVIDER: S-EPMC5407710 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
ACCESS DATA